Concurrent HER2 vaccination and inhibition of kinase activity: safety and immunogenicity.

about

Current Approaches and Emerging Directions in HER2-resistant Breast Cancer.Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.

P2860

Q34016480-9C2C10F2-5174-47E3-B010-C405100CA362 Q38215394-A3F42750-DCC8-460B-AE1B-DAD12104B479 Q38221107-DB33F8B2-3779-4BF9-BC5A-CCED75F79E1C

P2860

Concurrent HER2 vaccination and inhibition of kinase activity: safety and immunogenicity.

Item

http://www.wikidata.org/entity/Q46757140

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Concurrent HER2 vaccination and inhibition of kinase activity: safety and immunogenicity.

@en

Concurrent HER2 vaccination and inhibition of kinase activity: safety and immunogenicity.

@nl

type

Item

label

Concurrent HER2 vaccination and inhibition of kinase activity: safety and immunogenicity.

@en

Concurrent HER2 vaccination and inhibition of kinase activity: safety and immunogenicity.

@nl

prefLabel

Concurrent HER2 vaccination and inhibition of kinase activity: safety and immunogenicity.

@en

Concurrent HER2 vaccination and inhibition of kinase activity: safety and immunogenicity.

@nl

P1476

Concurrent HER2 vaccination and inhibition of kinase activity: safety and immunogenicity.

@en

P2093

Huguette Albrecht

http://www.w3.org/2001/XMLSchema#string

P2860

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Untangling the ErbB signalling network

Trastuzumab--mechanism of action and use in clinical practice

An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.

Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial

Anti-HER2 vaccines: new prospects for breast cancer therapy

Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy.

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications.

Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].

P304

671-674

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT.12.61

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22853752

http://www.w3.org/2001/XMLSchema#string

Concurrent HER2 vaccination and inhibition of kinase activity: safety and immunogenicity.

about

P2860

P2860

Concurrent HER2 vaccination and inhibition of kinase activity: safety and immunogenicity.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698